



## PRESS RELEASE

### Twenty-eighth meeting of the Management Board

The EMEA Management Board met on 20 December 2000. Prof. André Broekmans formally announced his resignation as chairman of the Board following his decision to leave the Dutch Medicines Evaluation Board. Prof. Gerhard Kothmann, the vice-chairman, chaired the meeting, which was also attended by Thomas Lönngren, Executive Director-designate. The election of the new chairman will take place at the Board's next meeting in February 2001.

A second supplementary and amending budget for 2000 was adopted to take into account increased fee revenue (€ 2 079 000) and other miscellaneous revenue. The 2000 budget now totals € 55 287 220.

The Management Board adopted a budget of € 61 934 000 for 2001. This includes forecast fee revenue of € 42 610 000, a basic contribution from the EU general budget of € 14 700 000, a special contribution for orphan medicinal products of € 600 000 and funding for Pan-European Regulatory Forum (PERF) II activities of € 2 440 000. The increase in the budget between 2000 and 2001 is mainly due to higher estimated fee revenue, the Agency's participation in the execution of the PERF II initiative, IT projects, extension and refurbishment of the EMEA offices and a small increase in staff from 210 in 2000 to 220.

The basis for distribution of fees between the EMEA and national competent authorities for the provision of rapporteur and other services was considered. The Board agreed to continue in 2001 with the current system under which half of most types of fees are paid to national authorities for rapporteur and inspection services, with a special distribution for annual fee revenue.

Following the workshop on EMEA transparency held on 23 November 2000, the Board discussed the recommendations made by the workshop. The workshop meeting report, together with contributions made by participants, is available on the EMEA web site. The Board will return to the matter at its February 2001 meeting to look at the practical aspects for the implementation of the recommendations.

The Board approved the EMEA Annual Report for 2000. The report will be made public at the beginning of 2001 once final figures have been included.

The Commission representatives updated the Management Board on progress with the 2001 review of the European marketing authorisation system. Following the publication of their consultants' report, a workshop with interested parties will be organised by the Commission on 26 January 2001. The Board also welcomed the adoption by the Commission of a Communication on the availability of veterinary medicines.

The next meeting of the Management Board will be on 21-22 February 2001.

#### NOTES FOR EDITORS:

1. This press release, together with other information about the work of the EMEA, may be found on the Internet at the following location: <http://www.eudra.org/emea.html>
2. The Communication on the availability of veterinary medicinal products (COM (2000) 806) is available from the European Commission in all official EU languages
3. The consultant report on the revision of the European marketing authorisation system is available from the web site of the Commission Pharmaceutical Unit <http://pharmacos.eudra.org>

Contacts for further information:

Martin Harvey or Antoine Cuvillier, EMEA Directorate  
Tel. (44-20) 7418 8427 / 8428  
Fax (44-20) 7418 8409